Evidence map›Paper›PMID 40281661›Full record

ArticleCancer medicine2025

Characterization of the Biochemical Recurrence Prediction Ability and Progression Correlation of Peroxiredoxins Family in Prostate Cancer Based on Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Cohorts.

Shan Tang, Jinchuang Li, Weicheng Tian, Yuanfa Feng, Yulin Deng, Zeheng Tan, Zhaodong Han, Huichan He, Yongding Wu, Chuyang Huang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shan TangUrology Department, The Central Hospital of Shaoyang, Shaoyang, China.
Jinchuang LiDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Weicheng TianGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Yuanfa FengGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Yulin DengDepartment of Urology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Zeheng TanDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Zhaodong HanDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Huichan HeGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Yongding WuGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Chuyang HuangUrology Department, The Central Hospital of Shaoyang, Shaoyang, China.
Keping NingUrology Department, The Central Hospital of Shaoyang, Shaoyang, China.
Feng LiuUrology Department, The Central Hospital of Shaoyang, Shaoyang, China.
Hongwei LuoUrology Department, The Central Hospital of Shaoyang, Shaoyang, China.
Shanghua CaiGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jianheng YeDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Weide ZhongDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.

Funding

Guangzhou Municipal Science and Technology Project 202201020346Health Commission of Hunan Province No:202204053584National Natural Science Foundation of China 82373166The National Key clinical specialty Major Scientific research Project No: Z2023145Youth Medical Innovation and Practice Research Program of Guangzhou 2023QNYXZD004
6 · The paper itself

Abstract

introductionThe peroxiredoxins (PRDXs) family plays a crucial role in balancing reactive oxygen species (ROS) levels in tumor cells. However, its potential role in prognosis and therapy response of prostate cancer (PCa) remains unknown.

methodsIn this study, we utilized 2 public single-cell RNA datasets and 8 bulk-RNA datasets to investigate the clinical value of six PRDXs family members in PCa. Expression comparison, biochemical recurrence analysis, and therapy response analysis were measured. Pathway enrichments were utilized to predict the potential down-stream pathway it may involve. In vitro experiments were used to validate the function of PRDX5 in the progression of castration-resistant prostate cancer (CRPC) cell lines.

resultAmong the PRDXs family, PRDX5 was most related to the advancement of prostate cancer. A nomogram integrating the expression of PRDX5 with clinical features was developed to better predict clinical outcomes in PCa patients compared to 30 published signatures. Immunohistochemistry was used to verify that PRDX5 expression was higher in advanced levels of PCa tissue. Gene Set Enrichment Analysis (GSEA) and pathway predictive analysis revealed that the PRDX5 related genes were mainly relevant to ROS Pathway, Mitochondria-related functions, cellular respiration, and oxidative phosphorylation. In vitro cell proliferation assays, ROS determination assay, and apoptosis assay together revealed that depletion of PRDX5 induces apoptosis via ROS accumulation in CRPC cells. Moreover, the expression of PRDX5 in CRPC cells also affects the sensitivity to the ARSI therapy.

conclusionThis study offers new evidence for determining that the expression of PRDX5 is associated with advanced tumor grade, poor prognosis, and suboptimal response to multiple therapies in PCa within the PRDXs family. Last but not least, our study provides new insights into precision medicine in PCa and provides a reference for further research on PRDX5.

Indexed as

Biomarkers, TumorNeoplasm Recurrence, LocalPeroxiredoxinsProstatic NeoplasmsApoptosisCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleNomogramsPrognosisReactive Oxygen SpeciesRNA-SeqSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisBiomarkers, TumorPeroxiredoxinsPRDX5 protein, humanReactive Oxygen Speciesbiochemical recurrenceperoxiredoxinsPRDX5prostate cancer

Identifiers

PMID40281661
PMCPMC12031674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.